MARKET

HALO

HALO

Halozyme
NASDAQ

Real-time Quotes | Nasdaq Last Sale

17.50
-0.41
-2.29%
Closed 16:56 03/27 EDT
OPEN
17.18
PREV CLOSE
17.91
HIGH
17.91
LOW
16.87
VOLUME
1.30M
TURNOVER
--
52 WEEK HIGH
22.06
52 WEEK LOW
12.71
MARKET CAP
2.42B
P/E (TTM)
-34.7567
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of HALO and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 11 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average HALO stock price target is 24.20 with a high estimate of 35.00 and a low estimate of 12.00.

EPS

HALO News

More
  • Halozyme Therapeutics, Inc. (HALO): Are Hedge Funds Right About This Stock?
  • Insider Monkey · 9h ago
  • Halozyme Therapeutics (HALO) Down 20.1% Since Last Earnings Report: Can It Rebound?
  • Zacks · 4d ago
  • Is Halozyme Therapeutics (HALO) Stock a Solid Choice Right Now?
  • Zacks · 03/19 15:30
  • The Daily Biotech Pulse: AbbVie, Allergan Agree On Divestments, Obalon Stops Obesity Balloon Sale, COVID-19 Updates
  • Benzinga · 03/18 11:36

Industry

Biotechnology & Medical Research
-2.43%
Pharmaceuticals & Medical Research
-0.87%

Hot Stocks

Symbol
Price
%Change

About HALO

Halozyme Therapeutics, Inc. is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of human enzymes and other drug candidates. The Company's segment also includes research and development activities and product sales of Hylenex recombinant. The Company's development pipeline consists of clinical-stage product candidates in oncology. Its lead oncology program is PEGPH20 (polyethylene glycol (PEG)ylated recombinant human hyaluronidase), a molecular entity being developed for the systemic treatment of tumors, which accumulate HA. It is in Phase II and Phase III clinical testing for PEGPH20 in stage IV pancreatic ductal adenocarcinoma (Studies 109-202 and 109-301); Phase Ib clinical testing in non-small cell lung cancer (Study 107-201), and in Phase Ib clinical testing in non-small cell lung cancer and gastric cancer (Study 107-101).
More

Webull offers kinds of Halozyme Therapeutics, Inc. stock information, including NASDAQ:HALO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, HALO stock news, and many more online research tools to help you make informed decisions.